Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of AOP200704 vs. Esmolol in Healthy Subjects
NCT01313143Phase 2Completed
- Sponsor
- AOP Health
- Start
- Mar 2011
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of landiolol in supraventricular tachycardia (SVT) (2 arms), sponsored by AOP Health. Primary endpoints: Pharmacokinetics and Pharmacodynamics at 9 hours, Dose to suppress Dobutamine induced heart rate increase at 9 hours and 2 more. Started Mar 2011; status: completed.
02
Drugs
landiolol
03
Conditions
supraventricular tachycardia (SVT)
Beyond the preview
Go deeper on NCT01313143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01313143.